FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4383215748> ?p ?o ?g. }

• W4383215748 endingPage "112965" @default.
• W4383215748 startingPage "112965" @default.
• W4383215748 abstract "Purpose The safety and objective clinical responses were observed in the phase I study using adjuvant autologous tumour-infiltrating lymphocytes (TILs) following concurrent chemoradiotherapy (CCRT) in nasopharyngeal carcinoma (NPC) patients. Methods and materials One hundred fifty-six patients with stage III–IVb and pretreatment Epstein–Barr virus DNA levels of ≥4000 copies/ml were randomly assigned to receive CCRT combined with TIL infusion (n = 78) or CCRT alone (n = 78). All patients received CCRT and patients assigned to the TIL group received TIL infusion within 1 week after CCRT. The primary endpoint was investigator-assessed progression-free survival (PFS) at 3 years. Results After a median follow-up of 62.3 months, no significant difference was observed in the 3-year PFS rate between the CCRT plus TIL infusion group and CCRT alone group (75.6% versus 74.4%, hazard ratios, 1.08; 95% confidence intervals, 0.62–1.89). TIL infusion was safe without grade 3 or 4 adverse events and all the high-grade adverse effects were associated with myelosuppression caused by CCRT. Exploratory analysis showed that a potential survival benefit was observed with TILs in patients with lower levels of circulating CD8+TIM3+ cells, serum IL-8 or PD-L1. The infused TIL products in patients with favourable outcomes were associated with increased transcription of interferon-γ and a series of inflammatory related genes and a lower exhausted score. Conclusion The primary objective of prolonging PFS with CCRT plus TILs in high-risk NPC patients was not met. These findings may provide evidence for the design of future trials investigating the combination of TILs plus immune checkpoint inhibitors based on CCRT in high-risk NPC patients. Trial registration number NCT02421640" @default.
• W4383215748 created "2023-07-06" @default.
• W4383215748 creator A5004188977 @default.
• W4383215748 creator A5011116669 @default.
• W4383215748 creator A5014737817 @default.
• W4383215748 creator A5021615345 @default.
• W4383215748 creator A5026796732 @default.
• W4383215748 creator A5030927144 @default.
• W4383215748 creator A5034488277 @default.
• W4383215748 creator A5037467201 @default.
• W4383215748 creator A5039009783 @default.
• W4383215748 creator A5047533905 @default.
• W4383215748 creator A5057532517 @default.
• W4383215748 creator A5059928860 @default.
• W4383215748 creator A5061152137 @default.
• W4383215748 creator A5061209676 @default.
• W4383215748 creator A5066696317 @default.
• W4383215748 creator A5069612314 @default.
• W4383215748 creator A5074832463 @default.
• W4383215748 creator A5078170323 @default.
• W4383215748 creator A5078326314 @default.
• W4383215748 creator A5083022490 @default.
• W4383215748 creator A5084047711 @default.
• W4383215748 date "2023-09-01" @default.
• W4383215748 modified "2023-10-16" @default.
• W4383215748 title "A phase II randomised controlled trial of adjuvant tumour-infiltrating lymphocytes for pretreatment Epstein-Barr virus DNA-selected high-risk nasopharyngeal carcinoma patients" @default.
• W4383215748 cites W1965029629 @default.
• W4383215748 cites W1968017437 @default.
• W4383215748 cites W1978505174 @default.
• W4383215748 cites W1982713075 @default.
• W4383215748 cites W2000929706 @default.
• W4383215748 cites W2019328052 @default.
• W4383215748 cites W2067586272 @default.
• W4383215748 cites W2077994554 @default.
• W4383215748 cites W2096932117 @default.
• W4383215748 cites W2105955346 @default.
• W4383215748 cites W2113470349 @default.
• W4383215748 cites W2120020619 @default.
• W4383215748 cites W2125919881 @default.
• W4383215748 cites W2138066012 @default.
• W4383215748 cites W2142047025 @default.
• W4383215748 cites W2147240268 @default.
• W4383215748 cites W2149209349 @default.
• W4383215748 cites W2149721689 @default.
• W4383215748 cites W2153712501 @default.
• W4383215748 cites W2155026493 @default.
• W4383215748 cites W2161043223 @default.
• W4383215748 cites W2162184613 @default.
• W4383215748 cites W2325631707 @default.
• W4383215748 cites W2559861554 @default.
• W4383215748 cites W2604931745 @default.
• W4383215748 cites W2615907969 @default.
• W4383215748 cites W2889646458 @default.
• W4383215748 cites W2907549567 @default.
• W4383215748 cites W2946348245 @default.
• W4383215748 cites W2947165726 @default.
• W4383215748 cites W2949177718 @default.
• W4383215748 cites W2953151710 @default.
• W4383215748 cites W2961573354 @default.
• W4383215748 cites W2972117761 @default.
• W4383215748 cites W3035139652 @default.
• W4383215748 cites W3045732472 @default.
• W4383215748 cites W3089967262 @default.
• W4383215748 cites W3092679796 @default.
• W4383215748 cites W3093383535 @default.
• W4383215748 cites W3111462718 @default.
• W4383215748 cites W3172428308 @default.
• W4383215748 cites W4304989474 @default.
• W4383215748 doi "https://doi.org/10.1016/j.ejca.2023.112965" @default.
• W4383215748 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37540921" @default.
• W4383215748 hasPublicationYear "2023" @default.
• W4383215748 type Work @default.
• W4383215748 citedByCount "0" @default.
• W4383215748 crossrefType "journal-article" @default.
• W4383215748 hasAuthorship W4383215748A5004188977 @default.
• W4383215748 hasAuthorship W4383215748A5011116669 @default.
• W4383215748 hasAuthorship W4383215748A5014737817 @default.
• W4383215748 hasAuthorship W4383215748A5021615345 @default.
• W4383215748 hasAuthorship W4383215748A5026796732 @default.
• W4383215748 hasAuthorship W4383215748A5030927144 @default.
• W4383215748 hasAuthorship W4383215748A5034488277 @default.
• W4383215748 hasAuthorship W4383215748A5037467201 @default.
• W4383215748 hasAuthorship W4383215748A5039009783 @default.
• W4383215748 hasAuthorship W4383215748A5047533905 @default.
• W4383215748 hasAuthorship W4383215748A5057532517 @default.
• W4383215748 hasAuthorship W4383215748A5059928860 @default.
• W4383215748 hasAuthorship W4383215748A5061152137 @default.
• W4383215748 hasAuthorship W4383215748A5061209676 @default.
• W4383215748 hasAuthorship W4383215748A5066696317 @default.
• W4383215748 hasAuthorship W4383215748A5069612314 @default.
• W4383215748 hasAuthorship W4383215748A5074832463 @default.
• W4383215748 hasAuthorship W4383215748A5078170323 @default.
• W4383215748 hasAuthorship W4383215748A5078326314 @default.
• W4383215748 hasAuthorship W4383215748A5083022490 @default.
• W4383215748 hasAuthorship W4383215748A5084047711 @default.
• W4383215748 hasConcept C121608353 @default.
• W4383215748 hasConcept C126322002 @default.
• W4383215748 hasConcept C143998085 @default.

• next